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Abstract: MicroRNAs (miRNAs) simultaneously modulate different oncogenic networks, establishing
a dynamic system of gene expression and pathway regulation. In this study, we analyzed global
miRNA and messenger RNA (mRNA) expression profiles of 17 cell lines representing different
molecular breast cancer subtypes. Spearman’s rank correlation test was used to evaluate the
correlation between miRNA and mRNA expression. Hierarchical clustering and pathway analysis
were also performed. Publicly available gene expression profiles (n = 699) and tumor tissues (n = 80)
were analyzed to assess the relevance of key miRNA-regulated pathways in human breast cancer. We
identified 39 significantly deregulated miRNAs, and the integration between miRNA and mRNA
data revealed the importance of immune-related pathways, particularly the Oncostatin M (OSM)
signaling, associated with mesenchymal-like breast cancer cells. OSM levels correlated with genes
involved in the inflammatory response, epithelial-to-mesenchymal transition (EMT), and epidermal
growth factor (EGF) signaling in human estrogen receptor (ER)-negative/human epidermal growth
factor receptor 2 (HER2)-negative breast cancer. Our results suggest that the deregulation of specific
miRNAs may cooperatively impair immune and EMT pathways. The identification of the OSM
inflammatory pathway as an important mediator of EMT in triple-negative breast cancer (TNBC)
may provide a novel potential opportunity to improve therapeutic strategies.
Keywords: breast cancer; microRNAs; molecular subtypes; immune response; Oncostatin M
1. Introduction
Breast cancer is a major cause of cancer death in women worldwide. Recent advancements in
the understanding of cancer biology and oncogenic mechanisms have led to the refinement of breast
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cancer classification, highlighting the molecular and clinical heterogeneity of this disease. Indeed,
distinct signaling pathways, genetic and epigenetic aberrations, and gene expression profiles have
been associated with different breast cancer subtypes [1–7]. In particular, triple-negative breast cancer
(TNBC), which lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2), encompasses a heterogeneous collection of tumors [8,9].
Specific TNBC subgroups are enriched for genes involved in the epithelial-to-mesenchymal transition
(EMT) process, which has been associated with cancer progression, poor prognosis, and resistance
to therapy [9]. Furthermore, cancer-related inflammation is now recognized as a hallmark of
cancer, and anti-tumor immune responses are emerging as important predictors of outcome and
response to therapies in TNBC [10,11]. Several molecular messengers, such as chemokines and
cytokines, are able to modulate the reciprocal interaction between breast cancer cells and the
immune microenvironment, thus supporting tumor development and progression [10]. Considering
the complexity and heterogeneity of breast cancer, the identification of reliable subtype-specific
molecules, which function to simultaneously modulate different oncogenic networks, may provide
novel insights into the dynamic architecture of cancer-related pathways and an opportunity to optimize
therapeutic strategies.
MicroRNAs (miRNAs) are recognized as master modulators of multiple biological and
pathological processes, establishing a complex combinatorial system of gene expression and pathway
regulation, as well as new therapeutic targets in different cancers [12,13]. Furthermore, recent studies
highlighted the relevance of miRNAs in regulating the crosstalk between cancer and immune cells in the
tumor microenvironment [14,15]. Deregulation of miRNAs expression through genetic and epigenetic
alterations, impairment of the biogenesis machinery, and alterations of the tumor microenvironment
(e.g., imbalance of immune cells and related cytokines), are frequently observed in human cancers,
including breast cancer [12–15].
In this study, we integrated miRNA–messenger RNA (mRNA) expression profiles to identify
specific pathway perturbations that characterize triple-negative/mesenchymal-like breast cancer cell
lines and human breast tumors.
2. Results
2.1. Specific miRNA Expression Patterns Define Molecularly Different Human Breast Cancer Cell Lines
We analyzed the genome-wide miRNA profiles of 17 cell lines representative of
different breast cancer molecular subtypes (Table S1) [16]. By selecting only miRNAs
expressed in at least nine cell lines, we identified 39 miRNAs significantly deregulated
between triple-negative/mesenchymal-like and non-mesenchymal-like (luminal/HER2-positive)
cells (Benjamini-Hochberg-adjusted p ≤ 0.05). Of these, 22 and 17 miRNAs were up-regulated and
down-regulated in the triple-negative/mesenchymal-like cells, respectively (Table 1).
Hierarchical clustering analysis revealed that the 17 breast cancer cell lines were separated
into two main branches based on differences in the expression of the 39 miRNAs (Figure 1).
Interestingly, the two HER2-positive cell lines (AU565 and SKBR3) formed a separate sub-cluster
of the non-mesenchymal-like branch, indicating the robustness of our classification (Figure 1). These
results indicate that miRNA expression profiles are able to characterize molecularly different breast
cancer cell lines, and confirm that intrinsic features of breast cancer subtypes are evident also at the
level of miRNAs expression.
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Table 1. The 39 significantly deregulated microRNAs (miRNAs) in triple-negative/mesenchymal-like
breast cancer cell lines.
Up-Regulated Down-Regulated
miRNA p-Value 1 miRNA p-Value 1
miR-29a 1.52 × 10−2 miR-34a 5.43 × 10−4
miR-31 6.26 × 10−3 miR-141 3.08 × 10−8
miR-100 8.54 × 10−3 miR-148a 5.49 × 10−4
miR-125b 1.98 × 10−2 miR-190b 8.54 × 10−3
miR-130a 1.90 × 10−2 miR-193a-3p 6.26 × 10−3
miR-138 4.41 × 10−3 miR-196a 3.08 × 10−2
miR-140-3p 1.06 × 10−2 miR-200a 6.32 × 10−7
miR-143 1.06 × 10−2 miR-200b 3.08 × 10−8
miR-145 2.69 × 10−2 miR-200c 2.85 × 10−7
miR-146a 4.01 × 10−3 miR-203 1.81 × 10−2
miR-146b-5p 6.24 × 10−3 miR-205 2.69 × 10−2
miR-155 3.86 × 10−3 miR-301a 7.13 × 10−3
miR-199a-3p/199b-3p 9.11 × 10−3 miR-335 1.05 × 10−2
miR-199a-5p 2.18 × 10−3 miR-363 8.86 × 10−3
miR-221 1.88 × 10−3 miR-375 1.49 × 10−2
miR-222 2.11 × 10−3 miR-429 1.06 × 10−2
miR-376c 3.66 × 10−5 miR-934 3.08 × 10−2
miR-455-3p 1.81 × 10−2
miR-582-5p 3.64 × 10−3
miR-886-3p 6.24 × 10−3
miR-886-5p 6.26 × 10−3
miR-1290 4.41 × 10−3
1 Benjamini-Hochberg adjusted p-value.
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Figure 1. Hierarchical clustering of the 39 most differentially expressed miRNAs in 17 breast cancer 
cell lines. Expression values of miRNAs are represented in a matrix format, with columns indicating 
miRNAs and rows indicating samples. High expression values are color-coded red, and low 
expression values are color-coded green. Hierarchical clustering of both miRNAs (columns) and 
samples (rows) are shown. 
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2.2. Correlation between miRNA and mRNA Expression Profiles and Pathway Analysis
To investigate the role of miRNAs in the regulation of multiple transcriptomic networks, we
assessed the correlation between the expression of the 39 selected miRNAs and the genome-wide
mRNA profiles of the 17 breast cancer cell lines. Collectively, we found 4813 genes significantly
correlated with the 39 deregulated miRNAs. Among these genes, we selected the mRNAs with the
highest absolute correlation values for each miRNA using a false discovery rate (FDR) threshold of
0.05 and performed a clustering analysis of miRNA–mRNA integrated profiles (Figure 2, Table S2).
The integration of expression data allowed for an accurate clustering of breast cancer cells into
mesenchymal-like and non-mesenchymal-like subtypes, with the exception of BT20 cell line (Figure 2).
This misclassification could be explained by the unclassified morphology of this TNBC cell line, as
reported by the American Type Culture Collection (ATCC; Table S1).
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Predicted and validated targets of the 39 significantly deregulated miRNAs were identified
using miRBase, TargetScan, and Tarbase tools. Only a few miRNAs showed an overlap between
the correlated mRNAs and the predicted targets (Table S3). Even though concordant genes may be
considered as direct miRNA targets, the reduced number of overlapping genes indicates that indirect
modulation mechanisms may be prevalent on direct target suppression, further strengthening the
complexity and the extensive regulatory role of miRNAs on gene expression in breast cancer.
Subsequently, we performed a pathway analysis to gain further insight into the biological
functions of these miRNAs in breast cancer. The association of correlated miRNAs-mRNAs with
related activated pathways is displayed in a heatmap with diverse colors corresponding to different
levels of significance (Figure 3). The most significant association (FDR ≤ 1.00 × 10−4) was found
between two miRNAs that were up-regulated in triple-negative/mesenchymal-like cells, miR-146b-5p
and miR-155, and the pathway of Oncostatin M (OSM), which is a member of the multifunctional
interleukin 6 (IL-6) family of cytokines (Figure 3). The OSM pathway was also consistently associated
with the expression of miR-31 (FDR ≤ 5.00 × 10−4), and miR-29a, miR-199a-3p/199b-3p, miR-199a-5p,
miR-200a, miR-221, and miR-222 (FDR level ≤ 5.00 × 10−3) (Table 2). Other immune-related and
oncogenic pathways were found to significantly correlate with specific miRNA-mRNA networks at
different FDR levels (Table 2).
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Table 2. The most relevant pathways related to miRNA–mRNA networks in breast cancer cell lines.
Signaling Pathway miRNA FDR
OSM signaling
miR-146b-5p, miR-155 ≤1.00 × 10−4
miR-31 ≤5.00 × 10−4
miR-29a, miR-199a-3p/199b-3p, miR-199a-5p, miR-200a, miR-221, miR-222 ≤5.00 × 10−3
miR-100, miR-125b, miR-143, miR-376c ≤1.00 × 10−2
miR-34a, miR-138, miR-141, miR-145, miR-146a, miR-148a, miR-200b,
miR-200c, miR-203 ≤5.00 × 10
−2
ERK/MAPK signaling
miR-138 ≤5.00 × 10−4
miR-376 ≤1.00 × 10−3
miR-100, miR-125b, miR-155 ≤5.00 × 10−3
miR-29a, miR-31, miR-141 ≤1.00 × 10−2
miR-34a, miR-146b-5p, miR-200a, miR-221, miR-222 ≤5.00 × 10−2
JAK/STAT pathway miR-155 ≤1.00 × 10−2
Integrin signaling miR-31, miR-138, miR-143, miR-145, miR-148a ≤5.00 × 10
−3
miR-29a, miR-200c ≤1.00 × 10−2
Interleukin-3 signaling
miR-155 ≤5.00 × 10−4
miR-31 ≤1.00 × 10−2
miR-29a, miR-145, miR-200a, miR-376 ≤5.00 × 10−2
Interleukin -4 signaling miR-31, miR-128a, miR-141, miR-148a, miR-155, miR-203 ≤5.00 × 10−2
Interleukin -6 signaling miR-140, miR-190b, miR-221, miR-222 ≤5.00 × 10−2
IFN-γ signaling miR-146b, miR-155 ≤5.00 × 10
−3
miR-31 ≤1.00 × 10−2
EGF signaling miR-31, miR-145, miR-155 <5.00 × 10−2
T helper differentiation pathway miR-220a ≤1.00 × 10
−2
miR-31, miR-130a, miR-145, miR-199a-5p, miR-203, miR-221, miR-375 ≤5.00 × 10−2
Semaphorins signaling miR-196a, miR-375, miR-429, miR-934 ≤5.00 × 10
−3
miR-145, miR-199a-5p, miR-200a, miR-203 ≤1.00 × 10−2
Leucocyte extravasation miR-200c ≤5.00 × 10
−3
miR-200b, miR-203 ≤1.00 × 10−2
Abbreviations: EGF, epidermal growth factor; ERK, extracellular signal–regulated kinases; IFN-γ, interferon-γ; JAK,
janus kinase; MAPK, mitogen-activated protein kinase, OSM, oncostatin M; STAT, signal transducer and activator
of transcription.
2.3. Oncostatin M Expression is Associated with ER-Negative/HER2-Negative Breast Cancer
Considering the key role of immune responses in breast cancer, we validated our
findings by analyzing gene expression data from three publicly available breast cancer datasets,
comprising 394 ER-positive (luminal; 56.4%), 262 ER-negative/HER2-negative (37.5%), and 43
ER-negative/HER2-positive (6.1%) breast cancers. We found that the expression of OSM and its
receptor (OSMR) were significantly higher in ER-negative/HER2-negative compared with that of
luminal/HER2-positive breast cancers (OSM, p = 3.90 × 10−2; OSMR, p = 2.80 × 10−3) (Figure 4A).
We confirmed this finding by analyzing the expression of the OSM protein in luminal (n = 40) and
triple-negative (n = 40) breast cancer samples (p = 6.00 × 10−3; Figure 4B,C).
To identify potential mechanisms mediating the effects of OSM signaling perturbation on tumor
cells and the immune microenvironment, we evaluated the correlation between OSM expression
and crucial oncogenic pathways, including inflammatory responses, EMT, epidermal growth factor
(EGF), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) cascades.
As expected, in silico analysis revealed that high levels of OSM expression significantly correlated
with several genes associated with macrophage functions and immune microenvironment, including
ARG1, CCL17, CCL24, CSF2, CXCL11, GAS7, IL1RN, IL4, IL6, and NFKB1 (Table 3). Interestingly, the
expression of OSM was also consistently associated with genes involved in EMT, EGF signaling, and
downstream pathways, including CDH1, EGFR, MAP2K7, MAP3K2, MTOR, PIK3R2, TGFB1, and ZEB2
(Table 3). Collectively, these results suggest that the deregulation of specific miRNA-mRNA networks
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could support the EMT process and contribute to the modulation of the cancer-immunity crosstalk in
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Table 3. Most significant correlations of OSM expression with cancer-related genes in ER-negative/
HER2-negative breast cancers (n = 262).
Category Gene SpearmanCoefficient 95% CI p-Value
Macrophage function
and immune response
ALOX15 0.442 0.34–0.54 <1.00 × 10−4
ARG1 0.512 0.34–0.54 <1.00 × 10−4
CCL17 0.218 0.10–0.33 4.00 × 10−4
CCL24 0.296 0.18–0.41 <1.00 × 10−4
CD40LG 0.335 0.22–0.44 <1.00 × 10−4
CERK 0.196 0.07–0.31 1.50 × 10−3
CHN2 0.282 0.16–0.39 <1.00 × 10−4
CSF2 0.382 0.27–0.48 <1.00 × 10−4
CSF3 0.451 0.35–0.55 <1.00 × 10−4
CSF3R 0.460 0.36–0.55 <1.00 × 10−4
CXCL9 −0.199 −0.32–−0.08 1.20 × 10−3
CXCL10 −0.196 −0.31–−0.07 1.40 × 10−3
CXCL11 −0.219 −0.33–−0.01 3.00 × 10−4
GAS7 0.306 0.19–0.42 <1.00 × 10−4
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Table 3. Cont.
Category Gene SpearmanCoefficient 95% CI p-Value
Macrophage function
and immune response
GBP1 −0.192 −0.31–−0.07 1.80 × 10−3
HRH1 0.250 0.13–0.36 <1.00 × 10−4
IL1RN 0.406 0.30–0.51 <1.00 × 10−4
IL4 0.378 0.27–0.48 <1.00 × 10−4
IL6 0.271 0.15–0.38 <1.00 × 10−4
IL6R 0.232 0.11–0.5 2.00 × 10−4
IL10 0.286 0.17–0.40 <1.00 × 10−4
IL15RA −0.228 −0.34–−0.11 2.00 × 10−4
IL17A 0.280 0.16–0.39 <1.00 × 10−4
IL32 −0.162 −0.28–−0.04 8.80 × 10−3
MERTK 0.162 0.04–0.28 8.60 × 10−3
NFKB1 0.385 0.27–0.49 <1.00 × 10−4
TNF 0.376 0.26–0.48 <1.00 × 10−4
EMT, EGF signaling and
downstream pathways
CDH1 −0.317 −0.42–−0.20 <1.00 × 10−4
COL1A2 −0.338 −0.44–−0.22 <1.00 × 10−4
COL3A1 −0.310 −0.42–−0.19 <1.00 × 10−4
DSP −0.227 −0.34–−0.10 2.00 × 10−4
EGFR 0.371 0.26–0.47 <1.00 × 10−4
MAP2K6 0.238 0.12–035 1.00 × 10−4
MAP2K7 0.466 0.36–056 <1.00 × 10−4
MAP3K2 0.358 0.24–0.46 <1.00 × 10−4
MAPK8 0.33 0.22–0.44 <1.00 × 10−4
MAPK10 0.272 0.15–0.38 <1.00 × 10−4
MTOR 0.385 0.27–0.49 <1.00 × 10−4
PIK3R2 0.213 0.09–0.33 5.00 × 10−4
RHOA 0.250 0.13–0.36 <1.00 × 10−4
SRC 0.237 0.12–0.35 1.00 × 10−4
TGFB1 0.446 0.34–0.54 <1.00 × 10−4
ZEB2 0.160 0.04–0.28 9.60 × 10−3
Abbreviations: CI, confidence interval; EMT, epithelial-to-mesenchymal transition; EGF, epidermal growth factor.
3. Discussion
Numerous studies investigated the value of miRNAs as molecular classifiers, as well as diagnostic,
prognostic, and predictive biomarkers in breast cancer [12,17–20]. Since miRNAs are able to modulate
multiple oncogenic processes by directly and indirectly regulating gene expression networks, the
integration of different -omics data represents a valuable strategy to understand the complex landscape
of cancer-related pathways, and to identify novel potential therapeutic targets [21–29]. Accordingly,
we showed that miRNA expression profiles are able to accurately characterize molecularly different
breast cancer cell lines, demonstrating that a specific pattern of miRNA expression could provide
important insights into breast cancer heterogeneity. Noteworthy, the integration of miRNA-mRNA
expression profiles allowed for the identification of key deregulated oncogenic pathways, especially
immune-related pathways, which could be involved in the development and progression of a
specific breast cancer subtype. In particular, we found that the up-regulation of miR-146b and
miR-155 in mesenchymal-like TNBC cell lines was consistently associated with perturbation of the
OSM pathway, which has been related to reduced expression of ER and poor outcome in breast
cancer [30]. Accordingly, our in silico and immunohistochemical analyses demonstrated the significant
up-regulation of both the cytokine and its receptor in TNBCs compared with other breast cancer
subtypes, supporting a role for the OSM signaling in this more aggressive subgroup of tumors.
Several studies demonstrated the involvement of OSM in the promotion of cell invasiveness
and migration, and in the acquisition of mesenchymal-like and stem cell-like features in breast
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cancer [31–34]. Moreover, OSM has been suggested to promote tumor aggressiveness through the
modulation of the inflammatory response, especially by inducing the recruitment of macrophages
at the tumor site and the polarization toward a pro-tumor M2 phenotype [35–39]. Consistent with
the pleiotropic role of OSM signaling in the regulation of mesenchymal-like TNBC cells-immune cells
interaction, we found significant associations between OSM levels and crucial oncogenic and immune
processes, including macrophage and immune functions, EMT, EGF signaling, and downstream
pathways. Therefore, targeting tumor-related inflammation and the cancer-associated immune cells
with pro-tumor functions may represent a novel therapeutic approach in mesenchymal-like TNBC.
4. Materials and Methods
4.1. Cell Culture, RNA Isolation, and Microarray Experiments
The breast cancer cell lines used in this study are described in Table S1. All cell lines were
grown and classified according to ATCC, and as previously reported [16]. Total RNA was extracted
using the standard TRIzol extraction procedures. After assessing RNA quality and yield with Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and NanoDrop ND1000 (NanoDrop
Technologies, Wilmington, DE, USA), samples were labeled with Cy5/Cy3 using a miRCURY LNA
microRNA array Power Labeling kit (Exiqon, Vedbaek, Denmark), and hybridized to Exiqon miRCURY
LNA miRNA array V.11.0 (Exiqon), that contains capture probes for all miRNAs registered in the
miRBase version 11.0 at the Sanger Institute (available on: http://www.mirbase.org). The quality
of labeling reaction and hybridization was evaluated using spike-in controls. Background corrected
and log2 transformed expression data were normalized using the global locally weighted scatterplot
smoothing (Lowess) regression algorithm, which we have found to produce the best within-slide
normalization and minimize the intensity-dependent differences between the dyes. Gene expression
profiling of breast cancer cell lines was performed using U133A Affymetrix chips containing 22,283
probe sets (Affymetrix, Santa Clara, CA, USA). Expression data were processed and normalized in
the R environment using the Robust Multiarray Analysis (RMA) algorithm implemented in the Affy
Bioconductor package (available on: http://www.bioconductor.org).
4.2. Human Breast Cancer Datasets and in Silico Analysis
To evaluate the biological crosstalk between interesting deregulated pathways in breast cancer,
publicly available gene expression profiles of breast cancer patients (n = 699) were collected from the
Gene Expression Omnibus (GEO) database (GSE25066, GSE23988, GSE20194). Gene expression data
were generated with Affymetrix U133A gene chips (Affymetrix) and normalized with the Microarray
Analysis Suite 5 (MAS5) algorithm, mean centered to 600 and log2 transformed using the Affy
Bioconductor library [4,5]. For genes targeted by multiple microarray probes, only the probe set with
the highest JetSet score was selected. ER and HER2 status were determined for each patient using
the probe sets 205225_at and 216836_s_at, respectively. Normalized values >10.18 of the probe set
205225_at were considered as ER-positive, and values > 12.54 for the probe set 216836_s_at were
considered as HER2-positive.
4.3. Tumor Samples and Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) tissues were retrospectively collected from patients
with histologically confirmed invasive ductal luminal (n = 40) or triple-negative (n = 40) breast cancers,
who underwent surgery at Humanitas Clinical and Research Institute (Rozzano-Milan, Italy). FFPE
sections (3 µm) were incubated with an anti-OSM antibody (Sigma-Aldrich, Milan, Italy) for 1 h
at room temperature. After washing with phosphate buffered saline (PBS), MACH 1 Universal
horseradish peroxidase (HRP) Polymer (Biocare Medical, Concord, CA, USA), and diaminobenzidine
(DAB; Biocare Medical) were used for chromogenic immunodetection, followed by counterstaining
with hematoxylin. Negative control slides without primary antibody and positive controls were used
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for each immunostaining run. Images were captured using an Olympus BX53 microscope (Olympus,
Tokyo, Japan). Semi-quantitative analysis of the staining intensity score was performed as previously
described [40]. Briefly, the staining intensity was assessed on a scale from 0 to 3 (0, negative; 1,
weak; 2, moderate; 3, strong), and staining percentage was scored from 0 to 4 (0, 0%–5% staining; 4,
75%–100% staining). A composite score was then calculated by multiplying the staining intensity by
the staining percentage.
4.4. Statistics and Bioinformatics
Differentially expressed miRNAs, mRNAs, and proteins were identified using an unpaired
t-test, and p-values were adjusted using a Benjamini-Hochberg multi-test correction as indicated
in the text. Spearman’s rank correlation test was performed to evaluate the correlation between
miRNAs and mRNAs. Hierarchical clustering analysis for miRNAs expression was performed using
Pearson’s distance metric and average linkage using GENE-E software (available on: https://software.
broadinstitute.org/GENE-E/index.html). Predicted and validated miRNA targets were identified
using miRBase version 21.0 (available on: http://www.mirbase.org/), TargetScan version 6.2 (available
on: http://www.targetscan.org), and Tarbase version 7 (available on: http://diana.cslab.ece.ntua.
gr/tarbase). Ingenuity pathway analysis software (Qiagen, Redwood City, CA, USA) was used
to define signaling pathways regulated by specific miRNAs in breast cancer cell lines. Significant
miRNA-pathway correlations were identified by controlling the FDR. All tests were two-sided and the
level of statistical significance was set at p ≤ 0.05. Statistical analyses were performed using GraphPad
Prism version 5 (GraphPad Software, La Jolla, CA, USA), and R software version 3.2.2 (available on:
http://www.r-project.org).
5. Conclusions
Collectively, our data show that specific miRNAs may have an important role as modulators
of immune and mesenchymal properties in human breast cancer. The identification of deregulated
miRNAs and related pathways may increase our understanding of the oncogenic functions that sustain
a specific tumor phenotype and provide a potential opportunity to optimize therapeutic strategies in
breast cancer.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/1/194/s1.
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